142 Chapter 6 analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort. Clin Microbiol Infect 2021; 27(1): 125.e1-.e6. 17. Kaliff M, Lillsunde Larsson G, Helenius G, Karlsson MG, Bergengren L. Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden. PLoS One 2022; 17(9): e0274825. 18. Al Roomy M, Chehadeh W, Al Awadhi R. Prediction of cervical cancer precursor lesions by quantitative methylation specific PCR: A retrospective study. Cytopathology 2023; 34(3): 204-10. 19. Dick S, Vink FJ, Heideman DAM, LissenbergWitte BI, Meijer C, Berkhof J. Riskstratification of HPV-positive women with low-grade cytology by FAM19A4/miR1242 methylation and HPV genotyping. Br J Cancer 2022; 126(2): 259-64. 20. De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer C, et al. Cervical cancer risk in HPVpositive women after a negative FAM19A4/ miR124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. Int J Cancer 2018; 143(6): 1541-8. 21. Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus cliniciancollected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screenpositive, non-inferiority trial. Lancet Oncol 2019; 20(2): 229-38. 22. Editorial Board WCoT. WHO Classification of Tumours Female Genital Tumours. 5th ed: International Agency for Research on Cancer; 2020. 23. Verlaat W, Snoek BC, Heideman DAM, Wilting SM, Snijders PJF, Novianti PW, et al. Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples. Clin Cancer Res 2018; 24(14): 3456-64. 24. Gold MR. Cost-Effectiveness in Health and Medicine: Oxford University Press, Inc.; 1996. 25. Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer C. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med 2019; 119: 108-17. 26. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106(5): 975-81. 27. Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM, et al. The clinical value of HPV genotyping in triage of women with highrisk-HPV-positive self-samples. Int J Cancer 2016; 139(3): 691-9. 28. Kremer WW, Berkhof J, Bleeker MC, Heideman DA, van Trommel NE, van Baal MW, et al. Role of FAM19A4/miR1242 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study. BMJ Open 2019; 9(7): e029017. 29. Kremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical Regression of HighGrade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/ miR124-2 DNA Methylation (CONCERVE Study). J Clin Oncol 2022; 40(26): 3037-46. 30. Louvanto K, Aro K, Nedjai B, Bützow R, Jakobsson M, Kalliala I, et al. Methylation in Predicting Progression of Untreated Highgrade Cervical Intraepithelial Neoplasia. Clin Infect Dis 2020; 70(12): 2582-90. 31. Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA
RkJQdWJsaXNoZXIy MjY0ODMw